Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for symptom relief in advanced cancer palliative care
ACTRN12618001220257Phase 2Completed
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer comparing Cannabidiol with Placebo (2 arms). Primary endpoint: Change from baseline of total composite ESAS TSDS. Started Feb 2019; status: completed.
02
Drugs
cannabidiol
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12618001220257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001220257.